Hypoxia activated prodrugs: Factors influencing design and development

Current Medicinal Chemistry

Volumn 22, Issue 37, 2015, Pages 4313-4325

  Liang, Dinghua ^a   Miller, Graham H ^a   Tranmer, Geoffrey K ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Antineoplastic agents; Bioreductive; Hypoxia; Prodrug; Targeted chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATIC NITRO COMPOUND; EVOFOSFAMIDE; HYDRAZINE DERIVATIVE; HYPOXIA ACTIVATED PRODRUG; INDUCIBLE NITRIC OXIDE SYNTHASE; KS 119; KS119W; METHIONINE SYNTHASE REDUCTASE; ORGANOPHOSPHATE; PR 104; PRODRUG; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE FERRIHEMOPROTEIN REDUCTASE; TIRAPAZAMINE; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL STRUCTURE; DRUG DESIGN; DRUG STABILITY; HUMAN; HYPOXIA; PATIENT CARE; CELL HYPOXIA; CHEMISTRY; DRUG DELIVERY SYSTEM; NEOPLASMS;

CELL HYPOXIA; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG STABILITY; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS; PRODRUGS;

EID: 84953775699     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867322666151021111016     Document Type: Article

References (73)

1. Höckel, M.; Vaupel, P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J. Natl. Cancer Inst., 2001, 93(4), 266-276.
2. Vaupel, P.; Kallinowski, F.; Okunieff, P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res., 1989, 49(23), 6449-6465.
3. Giaccia, A. J. Hypoxic stress proteins: survival of the fittest. Semin. Radiat. Oncol., 1996, 6(1), 46-58.
4. Cheng, K. C.; Loeb, L. A. Genomic instability and tumor progression: mechanistic considerations. Adv. Cancer Res., 1993, 60, 121-156.
5. Pouysségur, J.; Dayan, F.; Mazure, N. M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature, 2006, 441, 437-443.
6. Mandriota, S. J.; Pepper, M. S. Regulation of angiopoietin-2 mRNA levels in bovine microvascular endothelial cells by cytokines and hypoxia. Circ. Res., 1998, 83(8), 852-859.
7. Ikeda, E.; Achen, M. G.; Breier, G.; Risau, W. Hypoxiainduced transcriptional activation and increased mRNA sta bility of vascular endothelial growth factor in C6 glioma cells. J. Biol. Chem., 1995, 270(34), 19761-19766.
8. Wenzl, T.; Wilkens, J. J. Theoretical analysis of the dose dependence of the oxygen enhancement ratio and its relevance for clinical applications. Radiat. Oncol., 2011, 6, 171-171.
9. Höckel, M.; Schlenger, K.; Aral, B.; Mitze, M.; Schäffer, U.; Vaupel, P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res., 1996, 56(19), 4509-4515.
10. Cater, D. B.; Phillips, A. F. Measurement of electrode potentials in living and dead tissues. Nature, 1954, 174, 121-123.
11. Jiang, J.; Auchinvole, C.; Fisher, K.; Campbell, C. J. Quantitative measurement of redox potential in hypoxic cells using SERS nanosensors. Nanoscale, 2014, 6, 12104-12110.
12. Wilson, W. R.; Hay, M. P. Targeting hypoxia in cancer therapy. Nat. Rev. Cancer, 2011, 11, 393-410.
13. Denny, W.; Wilson, W.; Hay, M. Recent developments in the design of bioreductive drugs. Br. J. Cancer, 1996, 74(Suppl. XXVII), S32-S38.
14. Siim, B. G.; Denny, W. A.; Wilson, W. R. Nitro reduction as an electronic switch for bioreductive drug activation. Oncol. Res., 1997, 9, 357-369.
15. Wardman, P. Electron transfer and oxidative stress as key factors in the design of drugs selectively active in hypoxia. Curr. Med. Chem., 2001, 8, 739-761.
16. Denny, W. A.; Wilson, W. R. Considerations for the design of nitrophenyl mustards as agents with selective toxicity for hypoxic tumor cells. J. Med. Chem., 1986, 29, 879-887.
17. 2 inhibition of nitroreductase. Biochem. Biophys. Res. Commun., 1975, 67(4), 1267-1274.
18. Benov, L. How superoxide radical damages the cell. Protoplasma, 2001, 217, 33-36.
19. Fridovich, I. Superoxide dismutases. Adv. Enzymol. Relat. Areas Mol. Biol., 1986, 58, 61-97.
20. Laviron, E. R. L. The reduction mechanism of aromatic nitro compounds in aqueous medium. part 1. reduction to dihydroxylamines between pH 0 and 5. J. Electroanal. Chem., 1990, 288, 165-175.
21. Kovacic, P.; Kassel, M. A.; Feinberg, B. A.; Corbett, M. D.; Mcclelland, R. A. Reduction potentials in relation to physiological activities of benzenoid and heterocyclic nitroso compounds: comparison with the nitro precursors. Bioorg. Chem., 1990, 18(3), 265-275.
22. Beveridge, A. J.; Williams, M.; Jenkins, T. C. Calculation of one-electron reduction potentials for nitroheterocyclic hypoxia-selective agents. J. Chem. Soc., Faraday Trans., 1996, 92(5), 763-768.
23. Denny, W. A.; Wilson, W. R. Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs). Cancer Metastasis Rev., 1993, 12, 135-151.
24. Allalunis, M. J.; Chapman, J. D.; Turner, A. R. Identification of a hypoxic population of bone marrow cells. Int. J. Radiat. Oncol. Biol. Phys., 1983, 9(2), 227-232.
25. Nombela-Arrieta, C.; Pivarnik, G.; Winkel, B.; Canty, K. J.; Harley, B.; Mahoney, J. E.; Park, S.-Y.; Lu, J.; Protopopov, A.; Silberstein, L. E. Quantitative imaging of haematopoietic stem and progenitor cell localization and hypoxic status in the bone marrow microenvironment. Nat. Cell Biol., 2013, 15, 533-543.
26. Parmar, K.; Mauch, P.; Vergilio, J. A.; Sackstein, R.; Down, J. D. Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc. Natl. Acad. Sci. USA, 2007, 104(13), 5431-5436.
27. Parliament, M. B.; Wiebe, L. I.; Franko, A. J. Nitroimidazole adducts as markers for tissue hypoxia: mechanistic studies in aerobic normal tissues and tumour cells. Br. J. Cancer, 1992, 66, 1103-1108.
28. Lee, A. E.; Wilson, W. R. Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice. Toxicol. Appl. Pharmacol., 2000, 163(1), 50-59.
29. Evans, S. M.; Schrlau, A. E.; Chalian, A. A.; Zhang, P.; Koch, C. J. Oxygen levels in normal and previously irradiated human skin as assessed by EF5 binding. J. Invest. Dermatol., 2006, 126, 2596-2606.
30. Wardman, P. Reduction potentials of one-electron couples involving free radicals in aqueous solution. J. Phys. Chem. Ref. Data, 1989, 18(4), 1637-1755.
31. Meng, F.; Evans, J. W.; Bhupathi, D.; Banica, M.; Lan, L.; Lorente, G.; Duan, J.-X.; Cai, X.; Mowday, A. M.; Guise, C. P.; Maroz, A.; Anderson, R. F.; Patterson, A. V.; Stachelek, G. C.; Glazer, P. M.; Matteucci, M. D.; Hart, C. P. Molecular and cellular pharmacology of the hypoxiaactivated prodrug TH-302. Mol. Cancer Ther., 2012, 11(3), 740-751.
32. Pruijn, F. B.; Patel, K.; Hay, M. P.; Wilson, W. R.; Hicks, K. O. Prediction of tumour tissue diffusion coefficients of hypoxia-activated prodrugs from physicochemical parameters. Aust. J. Chem., 2008, 61(9), 687-693.
33. Foehrenbacher, A.; Patel, K.; Abbattista, M. R.; Guise, C. P.; Secomb, T. W.; Wilson, W. R.; Hicks, K. O. The role of bystander effects in the antitumor activity of the hypoxiaactivated prodrug PR-104. Front. Oncol., 2013, 3, article 263.
34. 2. J. Am. Chem. Soc., 2007, 129(42), 12870-12877.
35. Shinde, S. S.; Hay, M. P.; Patterson, A. V.; Denny, W. A.; Anderson, R. F. Spin trapping of radicals other than the •OH radical upon reduction of the anticancer agent tirapazamine by cytochrome P450 reductase. J. Am. Chem. Soc., 2009, 131(40), 14220-14221.
36. Wilson, W. R.; Hicks, K. O.; Pullen, S. M.; Ferry, D. M.; Helsby, N. A.; Patterson, A. V. Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards. Radiat. Res., 2007, 167, 625-636.
37. Patterson, A. V.; Ferry, D. M.; Edmunds, S. J.; Gu, Y.; Singleton, R. S.; Patel, K.; Pullen, S. M.; Hicks, K. O.; Syddall, S. P.; Atwell, G. J.; Yang, S.; Denny, W. A.; Wilson, W. R. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clin. Cancer. Res., 2007, 13, 3922-3932.
38. Guise, C. P.; Wang, A. T.; Theil, A.; Bridewell, D. J.; Wilson, W. R.; Patterson, A. V. Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH: cytochrome P450 oxidoreductase under hypoxia. Biochem. Pharmacol., 2007, 74, 810-820.
39. Guise, C. P.; Abbattista, M. R.; Tipparaju, S. R.; Lambie, N. K.; Su, J.; Li, D.; Wilson, W. R.; Dachs, G. U.; Patterson, A. V. Diflavin oxidoreductases activate the bioreductive prodrug PR-104A under hypoxia. Mol. Pharmacol., 2012, 81(1), 31-40.
40. Hunter, F. W.; Jaiswal, J. K.; Hurley, D. G.; Liyanage, H. D. S.; Mcmanaway, S. P.; Gu, Y.; Richter, S.; Wang, J.; Tercel, M.; Print, C. G.; Wilson, W. R.; Pruijn, F. B. The flavoprotein FOXRED2 reductively activates nitro chloromethylbenzindolines and other hypoxia-targeting prodrugs. Biochem. Pharmacol., 2014, 89, 224-235.
41. Guise, C. P.; Abbattista, M. R.; Singleton, R. S.; Holford, S. D.; Connolly, J.; Dachs, G. U.; Fox, S. B.; Pollock, R.; Harvey, J.; Guilford, P.; Doñate, F.; Wilson, W. R.; Patterson, A. V. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3. Cancer Res., 2010, 70(4), 1573-1584.
42. Jung, D.; Jiao, H.; Duan, J. X.; Matteucci, M.; Wang, R. Metabolism, pharmacokinetics and excretion of a novel hypoxia activated cytotoxic prodrug, TH-302, in rats. Xenobiotica, 2012, 42(4), 372-388.
43. Duan, J. X.; Jiao, H.; Kaizerman, J.; Stanton, T.; Evans, J. W.; Lan, L.; Lorente, G.; Banica, M.; Jung, D.; Wang, J.; Ma, H.; Li, X.; Yang, Z.; Hoffman, R. M.; Ammons, W. S.; Hart, C. P.; Matteucci, M. Potent and highly selective hypoxiaactivated achiral phosphoramidate mustards as anticancer drugs. J. Med. Chem., 2008, 51, 2412-2420.
44. Sun, J. D.; Liu, Q.; Wang, J.; Ahluwalia, D.; Ferraro, D.; Wang, Y.; Duan, J.-X.; Ammons, W. S.; Curd, J. G.; Matteucci, M. D.; Hart, C. P. Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer. Clin. Cancer. Res., 2012, 18(3), 758-770.
45. Su, J.; Gu, Y.; Pruijn, F. B.; Smaill, J. B.; Patterson, A. V.; Guise, C. P.; Wilson, W. R. Zinc finger nuclease knock-out of NADPH: cytochrome P450 oxidoreductase (POR) in human tumor cell lines demonstrates that hypoxia-activated prodrugs differ in POR dependence. J. Biol. Chem., 2013, 288(52), 37138-37153.
46. Hay, M. P.; Anderson, R. F.; Ferry, D. M.; Wilson, W. R.; Denny, W. A. Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy. J. Med. Chem., 2003, 46, 5533-5545.
47. Kim, E. Y.; Liu, Y.; Akintujoye, O. M.; Shyam, K.; Grove, T. A.; Sartorelli, A. C.; Rockwell, S. Preliminary studies with a new hypoxia-selective cytotoxin, KS119W, in vitro and in vivo. Radiat. Res., 2012, 178(3), 126-137.
48. Penketh, P. G.; Baumann, R. P.; Shyam, K.; Williamson, H. S.; Ishiguro, K.; Zhu, R.; Eriksson, E. S. E.; Eriksson, L. A.; Sartorelli, A. C., 1, 2-Bis (methylsulfonyl)-1-(2-chloroethyl) - 2-[[1-(4-nitrophenyl) ethoxy]carbonyl]hydrazine (KS119): a cytotoxic prodrug with two stable conformations differing in biological and physical properties. Chem. Biol. Drug Des., 2011, 78, 513-526.
49. a) Seow, H. A.; Penketh, P. G.; Shyam, K.; Rockwell, S.; Sartorelli, A. C., 1, 2-Bis (methylsulfonyl)-1-(2-chloroethyl) - 2-[[1-(4-nitrophenyl) ethoxy]carbonyl]hydrazine: An Anticancer Agent Targeting Hypoxic Cells. Proc. Natl. Acad. Sci. USA, 2005, 102(26), 9282-9287.
50. Shyam, K.; Penketh, P. G.; Baumann, R. P.; Finch, R. A.; Zhu, R.; Zhu, Y. L.; Sartorelli, A. C. Antitumor sulfonylhydrazines: design, structure-activity relationships, resistance mechanisms, and strategies for improving utility. J. Med. Chem., 2015, 58(9), 3639-3671.
51. Penketh, P. G.; Shyam, K.; Zhu, R.; Baumann, R. P.; Ishiguro, K.; Sartorelli, A. C. Influence of phosphate and phosphoesters on the decomposition pathway of 1, 2-Bis (methylsulfonyl)-1-(2-chloroethyhydrazine (90CE), the active anticancer moiety generated by laromustine, KS119, and KS119W. Chem. Res. Toxicol., 2014, 27(5), 818-833.
52. 6-alkylguanine-DNA alkyltransferase mediated KS119 tumor cell resistance. Biochem. Pharmacol., 2010, 79(11), 1553-1561.
53. Shyam, K.; Penketh, P. G.; Shapiro, M.; Belcourt, M. F.; Loomis, R. H.; Rockwell, S.; Sartorelli, A. C. Hypoxiaselective nitrobenzyloxycarbonyl derivatives of 1, 2-Bis (methylsulfonyl)-1-(2-chloroethyl) hydrazines. J. Med. Chem., 1999, 42(5), 941-946.
54. Paine, M. J. I.; Garner, A. P.; Powell, D.; Sibbald, J.; Sales, M.; Pratt, N.; Smith, T.; Tew, D. G.; Wolf, C. R. Cloning and characterization of a novel human dual flavin reductase. J. Biol. Chem., 2000, 275, 147150-591478.
55. Garner, A. P.; Paine, M. J. I.; Rodriguez-Crespo, I.; Chinje, E. C.; Montellano, P. O. D.; Stratford, I. J.; Tew, D. G.; Wolf, C. R. Nitric oxide synthases catalyze the activation of redox cycling and bioreductive anticancer agents. Cancer Res., 1999, 59, 1929-1934.
56. Aigrain, L.; Fatemi, F.; Frances, O.; Lescop, E.; Truan, G. Dynamic control of electron transfers in diflavin reductases. Int. J. Mol. Sci., 2012, 13, 15012-15041.
57. Finn, R. D.; Basran, J.; Roitel, O.; Wolf, C. R.; Munro, A. W.; Paine, M. J. I.; Scrutton, N. S. Determination of the redox potentials and electron transfer poperties of the FADand FMN-bnding dmains of the hman oidoreductase NR1. Eur. J. Biochem., 2003, 270, 1164-1175.
58. Munro, A. W.; Noble, M. A.; Robledo, L.; Daff, S. N.; Chapman, S. K. Determination of the redox properties of human NADPH-cytochrome P450 reductase. Biochemistry, 2001, 40, 1956-1963.
59. Gao, Y. T.; Smith, S. M. E.; Weinberg, J. B.; Montgomery, H. J.; Newman, E.; Guillemette, J. G.; Ghosh, D. K.; Roman, L. J.; Martasek, P.; Salerno, J. C. Thermodynamics of oxidation-reduction reactions in mammalian nitric-oxide synthase isoforms. J. Biol. Chem., 2004, 279, 18759-18766.
60. Wolthers, K. R.; Basran, J.; Munro, A. W.; Scrutton, N. S. Molecular dissection of human methionine synthase reductase: determination of the flavin redox potentials in fulllength enzyme and isolated flavin-binding domains. Biochemistry, 2003, 42(13), 3911-3920.
61. Stuehr, D. J.; Santolini, J.; Wang, Z. Q.; Wei, C. C.; Adak, S. Update on mechanism and catalytic regulation in the NO synthases. J. Biol. Chem., 2004, 279, 36167-36170.
62. Olteanu, H.; Banerjee, R. Human methionine synthase reductase, a soluble P-450 reductase-like dual flavoprotein, is sufficient for NADPH-dependent methionine synthase activation. J. Biol. Chem., 2001, 276(38), 35558-35563.
63. Riddick, D. S.; Ding, X.; Wolf, C. R.; Porter, T. D.; Pandey, A. V.; Zhang, Q.-Y.; Gu, J.; Finn, R. D.; Ronseaux, S.; Mclaughlin, L. A.; Henderson, C. J.; Zou, L.; Flück, C. E. NADPH-cytochrome P450 oxidoreductase: roles in physiology, pharmacology, and toxicology. Drug Metab. Disposition, 2013, 41, 12-23.
64. Patterson, A.; Barham, H.; Chinje, E.; Adams, G.; Harris, A.; Stratford, I. Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233). Br. J. Cancer, 1995, 72, 1144-1150.
65. Olteanu, H.; Banerjee, R. Redundancy in the pathway for redox regulation of mammalian methionine synthase reductive activation by the dual flavoprotein, novel reductase 1. J. Biol. Chem., 2003, 278, 38310-38314.
66. Guan, Z.-W.; Kamatani, D.; Kimura, S.; Iyanagi, T. Mechanistic studies on the intramolecular one-electron transfer between the two flavins in the human neuronal nitricoxide synthase and inducible nitric-oxide synthase flavin domains. J. Biol. Chem., 2003, 278, 30859-30868.
67. Thomsen, L. L.; Miles, D. W.; Happerfield, L.; Bobrow, L. G.; Knowles, R. G.; Moncada, S. Nitric oxide synthase ac tivity in human breast cancer. Br. J. Cancer, 1995, 72, 41-44.
68. Swana, H. S.; Smith, S. D.; Perrotta, P. L.; Saito, N.; Wheeler, M. A.; Weiss, R. M. Inducible nitric oxide synthase with transitional cell carcinoma of the bladder. J. Urol., 1999, 161(2), 630-634.
69. Chandor, L.; Dijols, S.; Ramassamy, B.; Frapart, Y.; Mansuy, D.; Stuehr, D.; Helsby, N.; Boucher, J. L. Metabolic activation of the antitumor drug 5-(aziridin-1-yl)-2, 4-dinitrobenzamide (CB1954) by NO synthases. Chem. Res. Toxicol., 2008, 21(4), 836-843.
70. Chinje, E. C.; Cowen, R. L.; Feng, J.; Sharma, S. P.; Wind, N. S.; Harris, A. L.; Stratford, I. J. Non-nuclear localized human NOSII enhances the bioactivation and toxicity of Tirapazamine (SR4233) in vitro. Mol. Pharmacol., 2003, 63(6), 1248-1255.
71. Riemer, J.; Appenzeller-Herzog, C.; Johansson, L.; Bodenmiller, B.; Hartmann-Petersen, R.; Ellgaard, L. A luminal flavoprotein in endoplasmic reticulum-associated degradation. Proc. Natl. Acad. Sci. USA, 2009, 106(35), 14831-14836.
72. Riemer, J.; Hansen, H. G.; Appenzeller-Herzog, C.; Johansson, L.; Ellgaard, L. Identification of the PDI-family member ERp90 as an interaction partner of ERFAD. PLoS One, 2011, 6(2), e17037.
73. Penning, T. M.; Drury, J. E. Human aldo-keto reductases: function, gene regulation, and single nucleotide polymorphisms. Arch. Biochem. Biophys., 2007, 464(2), 241-250.